Breast cancer · 2 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Pertuzumab and Trastuzumab Variant #01 | ERBB2 | R 78 133 | 21d | — | — | ~2 | ~R 104 177 indirect | — |
Trastuzumab monotherapy Variant #09 | ERBB2 | R 9 373 | 42d | — | — | ~10 | ~R 51 549 PFS proxy · indirect | 2 |
2 of 2 regimens shown